

Biologics Discovery Capabilities

- 200+ successful antibody discovery campaigns
- Dozens of biologics discovered/engineered in clinic
- End-to-end biologics discovery capabilities from antibody discovery to lead selection/optimization
- One-stop shop biologics capabilities from discovery, CLD, PD, cGMP manufacturing to DP





Bioassays

- Binding & Functional assays
- Viability & Fc effector assays (+Fc panel)
- Cancer cell killing assay
- Custom T cell & immune cell assays
- Potency, ADA, PK assay development
- Cell line engineering



Ab + Protein engineering

- Humanization
- Affinity maturation
- Sequence diversification
- Fc engineering
- Deimmunization



Discovery

mAb discovery:

- Single B cell Beacon® Optofluidic system, hybridoma, phage display, yeast display screening
- Fc panel, SPR/BLI, Epitope binning



Immunogenicity

- In silico immunogenicity prediction
- PBMC time course (CD4+)
- CRA
- T cell epitope mapping (TCEM)
- Custom DCT assay



Analytics

- Protein characterization
- Epitope mapping, peptide mapping, X-ray crystallography
- Pre-formulation, developability analytics



Chemistry, Bioconjugation

- Protein-, peptide- & other LM-drug conjugates
- Imaging and labeling conjugates
- Biotin, PEG or RNA (AOC) labelled conjugates
- Custom payload synthesis + optimization
- Radioimmuno conjugate – chelator



Transient + Stable Expression

- Transient protein expression
- Stable cell pool/line generation (IND enabling), material generation (2 L – 10 L)
- Non-mammalian expression



Developability + Pre-formulation

- Developability assessment
- Polyspecificity
- In silico liability assessment
- Immunogenicity assessment

Biologics


mAb
Discovery

Candidate screening/
lead selection

Lead candidate
optimization

Leads
scale-up

Discovery	✓			
Bioassay	Screening assay development	Screening assay PK	Characterization PK	✓
Immunogenicity		✓	Risk assessment	
Analytics		ID PK	Leads characterization PK, CQA, stability, pre-formulation	✓
Expression	✓	✓	✓	Stable pool and large scale transient
Developability		✓	✓	
Antibody engineering	✓	✓	✓	
Biomarker, PK, ADA, NAb reagent needs	✓	✓	✓	✓



“We worked with Curia on a monoclonal antibody discovery campaign. They were a fantastic scientific partner who delivered a panel of high-quality antibodies that have greatly enhanced our research efforts.”

Kareem Graham, Ph.D.
Senior Director, Immunology
Alumis, Inc.

“We worked with Curia Biologics on a therapeutic monoclonal antibody discovery campaign targeting LILRB2. They were a fantastic scientific partner who delivered a dual antagonistic antibody that have greatly enhanced our efforts in targeting MDSCs for cancer immunotherapy”

Bruce Daugherty, Ph.D., MBA
Executive Vice President, Research
Tonix Pharmaceuticals

ABOUT CURIA

Curia is a global contract research, development, and manufacturing organization (CDMO) with over 30 years of experience. With an integrated network of 20+ facilities worldwide and a team of 3,000+ dedicated professionals, we specialize in partnering with biopharmaceutical customers to bring life-changing therapies to market.

Our offerings in small molecules, generic APIs, and biologics span discovery through commercialization, with integrated regulatory, analytical, and sterile fill-finish capabilities. Our scientific and process experts, along with our regulatory-compliant facilities, deliver a best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we are your trusted ally in accelerating life-changing therapeutics.

To learn more, visit us at curiaglobal.com

